General Information
Acalabrutinib is an oral inhibitor of Bruton’s tyrosine kinase. Acalabrutinib is used in treatment of mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other chemotherapy medication. It is also used to treat chronic lymphocytic leukemia (CLL; a type of cancer in which the bone marrow makes too many lymphocytes) and small lymphocytic lymphoma (SLL: where cancer cells are found mostly in the lymph nodes).
About the API
Systematic name
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
Technology
Synthetic
Molecular Formula
C26H23N7O2
Molecular Weight
465.5 g/mol
Therapeutic category
Oncology
Available formulations
Oral Solid